Jaguar Health (JAGX) Income from Non-Controlling Interests (2022 - 2026)
Jaguar Health (JAGX) posted quarterly Income from Non-Controlling Interests of -$126000.0 for Q1 2026, up 4.55% year-over-year from -$120521.7 in Q1 2025, and up 4.55% quarter-over-quarter from -$132000.0 in Q1 2025.
Jaguar Health (JAGX) Income from Non-Controlling Interests (2022 - 2026) Analysis & Trends
Jaguar Health (JAGX) has reported Income from Non-Controlling Interests for 5 consecutive years, with -$126000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Non-Controlling Interests rose 4.55% year-over-year to -$126000.0; the TTM figure through Mar 2026 stood at -$536000.0 (up 2.37% YoY), while the FY2025 annual figure was -$563000.0, up 25.82% from the prior year.
- Income from Non-Controlling Interests improved to -$126000.0 in Q1 2026 per JAGX's latest filing, from -$132000.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at -$23000.0 in Q2 2022 and bottomed at -$651000.0 in Q4 2022.
- Historically, Income from Non-Controlling Interests has averaged -$173166.7 across 5 years, with a median of -$137500.0 in 2023.
- On a YoY basis, Income from Non-Controlling Interests climbed as much as 78.65% in 2023 and fell as far as 513.04% in 2023.
- Jaguar Health's Income from Non-Controlling Interests stood at -$651000.0 in 2022, then jumped by 78.65% to -$139000.0 in 2023, then climbed by 2.16% to -$136000.0 in 2024, then increased by 2.94% to -$132000.0 in 2025, then increased by 4.55% to -$126000.0 in 2026.
- Business Quant data shows JAGX's Income from Non-Controlling Interests at -$126000.0 in Q1 2026, -$132000.0 in Q1 2025, and -$136000.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 63.60 Mn |
| 10 | Jaguar Health | 447,549.24 | -9.62 Mn | 19.11 Mn | -126,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -126,000.00 |
| Mar 31, 2025 | -132,000.00 |
| Jun 30, 2024 | -136,000.00 |
| Mar 31, 2024 | -142,000.00 |
| Dec 31, 2023 | -139,000.00 |
| Sep 30, 2023 | -126,000.00 |
| Jun 30, 2023 | -141,000.00 |
| Mar 31, 2023 | -195,000.00 |
| Dec 31, 2022 | -651,000.00 |
| Sep 30, 2022 | -89,000.00 |
| Jun 30, 2022 | -23,000.00 |
| Mar 31, 2022 | -178,000.00 |